Eurofarma Balance Sheet 2020 | Base Year 2019
Published in: March 30, 2020
and updated in: November 4, 2021
Listen to the text
Stop the audio
São Paulo, March 2020 – Eurofarma’s Balance Sheet for the base year of 2019 was published on the Brazilian newspaper Valor Econômico on March 30. The report allows stakeholders and other interested parties to access Eurofarma’s key social, environmental and economic indicators for the last fiscal year.
By sharing its figures with the market, Eurofarma continues to learn and prioritize the medium and long term, ensure transparent activities and demonstrate its solidity. The company reinforces its strive for sustainability by consistently investing in the triad of Innovation, Marketing and Internationalization.
Among the main results of 2019 are the 27% Ebidta growth and gross sales totaling BRL 5.6 billion, up 29% over the previous year and 16% over the last 15 years, on average. Another milestone was the fact that the company took the lead in Medical Prescription, totaling 8.3% in market share, as well as better results from international operations to achieve consistent results across all 20 countries.
Alongside Sustainability, Innovation remains one of the key themes to be disseminated across the entire company. Therefore, the company will invest BRL 361 million in Research & Development in 2020.
Click here to view the Eurofarma Balance Sheet 2020 | Base Year 2019.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma_br | Twitter: @eurofarmaLab
By sharing its figures with the market, Eurofarma continues to learn and prioritize the medium and long term, ensure transparent activities and demonstrate its solidity. The company reinforces its strive for sustainability by consistently investing in the triad of Innovation, Marketing and Internationalization.
Among the main results of 2019 are the 27% Ebidta growth and gross sales totaling BRL 5.6 billion, up 29% over the previous year and 16% over the last 15 years, on average. Another milestone was the fact that the company took the lead in Medical Prescription, totaling 8.3% in market share, as well as better results from international operations to achieve consistent results across all 20 countries.
Alongside Sustainability, Innovation remains one of the key themes to be disseminated across the entire company. Therefore, the company will invest BRL 361 million in Research & Development in 2020.
Click here to view the Eurofarma Balance Sheet 2020 | Base Year 2019.
About Eurofarma Group
As the first multinational pharmaceutical company with 100% Brazilian capital, the Eurofarma Group has been operating in the health industry since its establishment in 1972, producing and marketing innovative products and services to improve people’s quality of life. Focused on generating shared value, it operates in the areas of Prescription, Non-Prescription, and Generic Drugs, Hospital, Oncology and Veterinary. In Brazil alone, it offers 313 products, 649 dosage forms, serves 25 medical specialties and covers 89 therapeutic classes, which represent 81% of prescriptions in the brand market.
The Eurofarma Group has own operations in 20 countries, with an industrial park in Brazil and plants in 6 more Latin American countries. Reported sales totaled BRL 5.6 billion in 2019 and the Group employs over 7,000 employees.
Eurofarma in social media
Facebook: @eurofarma | LinkedIn: @eurofarma
Instagram: @eurofarma_br | Twitter: @eurofarmaLab